Trial Profile

Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia.Safety Issues

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2020 However, the primary efficacy outcome is also stated as main efficacy endpoint (MEO) & as secondary outcome of this study in rest of the same results source (3411796).In this case, main efficacy endpoint is not the primary endpoint of the study rather it is MEO amongst all other efficacy endpoints. Hence, retained only safety as primary endpoint of this study.
25 Jul 2019 Results assessing the safety and preliminary efficacy of injecting onabotulinumtoxinA (BTA) toward the sphenopalatine ganglion using the MultiGuide in patients with refractory classical trigeminal neuralgia, were published in the Headache Journal.
08 Nov 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com